Evidence map›Paper›PMID 42219654›Full record

ReviewGut microbes2026

Rethinking probiotics: breaking the

Claudia Cappella, Chiara Redaelli, Melissa Balzarotti, Pasquale Scarcia, Gennaro Agrimi, Maurizio Bettiga

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Claudia CappellaDepartment of Biosciences, Biotechnologies and Environment, University of Bari "Aldo Moro", Campus Universitario, Bari, Italy.ORCID 0009-0003-4081-6338
Chiara RedaelliConsorzio Italbiotec, Milan, Italy.ORCID 0009-0002-7970-1194
Melissa BalzarottiConsorzio Italbiotec, Milan, Italy.ORCID 0000-0002-7845-2643
Pasquale ScarciaDepartment of Biosciences, Biotechnologies and Environment, University of Bari "Aldo Moro", Campus Universitario, Bari, Italy.ORCID 0000-0001-6216-0411
Gennaro AgrimiDepartment of Biosciences, Biotechnologies and Environment, University of Bari "Aldo Moro", Campus Universitario, Bari, Italy.ORCID 0000-0002-5219-4412
Maurizio BettigaItalbiotec Srl Società Benefit, Milan, Italy.ORCID 0000-0001-5934-8720

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past two decades, gut microbiota has emerged as a central regulator of host metabolism and immune homeostasis, leading to extensive clinical and translational exploration of probiotic interventions. However, despite increasing recognition of microbiota complexity, clinical and translational research has remained disproportionately focused on a limited set of taxa, primarily

Indexed as

BifidobacteriumDysbiosisGastrointestinal MicrobiomeHypersensitivityLactobacillusProbioticsAnimalsHumansallergic diseasedysbiosisLactobacillus and Bifidobacteriummicrobiota-immune interactionsnext-generation probioticsProbiotics

Identifiers

PMID42219654
PMCPMC13228984

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.